智通财经APP获悉,8月12日,第一三共宣布,其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市,适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。

德曲妥珠单抗(DS-8201,商品名:优赫得®/Enhertu)是一款靶向HER2的ADC药物,由第一三共开发,并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成,DAR约为8。
智通财经APP获悉,8月12日,第一三共宣布,其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市,适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。

德曲妥珠单抗(DS-8201,商品名:优赫得®/Enhertu)是一款靶向HER2的ADC药物,由第一三共开发,并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成,DAR约为8。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.